Logo

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Share this

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Shots:

  • The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the first 8 wks.& the last 4wks and with enalapril and then switched to Entresto for the last 4wks.
  • The PIONEER-HF 4-week extension study results: change in NT-proBNP (-18.5% vs -35.8%); symptomatic hypotension (2.9% vs 3.9%); hyperkalemia (2.4% vs 4.1%); Worsening renal function (8.6% vs 9.6%); no angioedema events; @12 wks. relative risk reduction 33%
  • Entresto (sacubitril/valsartan- bid- 50/100/200 mg) is a heart failure therapy used to reduce the strain on failing heart by improving neurohormonal systems and inhibiting the effect of overactive RAAS

Click  here Ref: Novartis | Image: Daily Record 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions